CClinicalTrials.gg
RecruitingNCT05287841Updated Sep 20, 2024

Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?

An interventional study of Batten batten graft and Septoplasty in Nasal Obstruction, Septal Defect and Allergic Rhinitis, sponsored by Northwell Health. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Northwell Health · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the effectiveness of batten grafts plus septoplasty and turbinate reduction (intervention arm) compared to septoplasty and turbinate reduction alone (control arm), both in terms of subjective and objective assessments.

Read the detailed description

One of the most common reasons to pursue nasal surgery is for nasal obstruction caused by a septal deviation. Otolaryngologists frequently perform septoplasties to improve nasal obstruction due to septal deviation, leading to improved airflow and decrease office visits and medication use. Concurrently with septal deviations, the inferior turbinate tends to become hypertrophied on the contralateral side potentially causing additional nasal obstruction. While septal deviations and inferior turbinate hypertrophy are more anatomical causes of nasal obstruction, there are also other types that vary depending on nasal airflow, such as nasal valve collapse. One way to surgically correct such dynamic nasal obstruction includes alar batten grafts. These grafts are not meant to change the anatomy of the nose, but instead, function to support the weakened lateral wall. Expanding the current septoplasty procedure to include batten grafts as well as inferior turbinate reduction could possibly improve long-term outcomes, especially reducing future surgeries.

02

Conditions studied

  • Nasal Obstruction
  • Septal Defect
  • Allergic Rhinitis
  • Nasal Polyps
  • Nasal Valve Collapse
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients should satisfy all the following criteria to be considered eligible for randomization:

    1. Be age 18 or above
    2. Able to provide written informed consent
    3. Have an indication for batten graft, septoplasty and turbinate reduction according to prevailing surgical practices.

    <!-- -->

    1. Septal deviation must be present on direct or endoscopic examination
    2. Inferior turbinate hypertrophy must be present, direct examination or endoscopic examination
    3. Collapse of external nasal valve and/or lateral motion instability must be documented

    <!-- -->

    1. The ENV maye be assessed clinically by observing the alar collapse at baseline or with forced inspiration, Modified cottle may also be performed.

In all patients, endoscopic examination should document that the (a) septal deviation, (b) turbinate hypertrophy, and (c) external nasal valve collapse are the primary contributing factors of obstructed breathing.

Exclusion criteria

Exclusion Criteria:

  1. Septal perforation
  2. History of previous functional rhinoplasty or sinus or septal surgery
  3. Patients who are selected for concurrent aesthetic/cosmetic rhinoplasty
  4. Untreated allergic rhinitis or allergic rhinitis unresponsive to medical management
  5. Patients who have concurrent sinus surgery or polyp removal or concha bullosa resection
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Batten graft, plus septoplasty and inferior turbinate reduction

    In the intervention arm, a portion of the quadrangular cartilage of the nasal septum is also removed, but will be refashioned and re-implanted into the patient as an autologous batten graft. This will be performed together with standard septoplasty and turbinate reduction.

    Procedure: Batten batten graft · Procedure: Septoplasty · Procedure: Inferior Turbinate Reduction

  • Active comparator
    Septoplasty and inferior turbinate reduction alone

    In the control arm, a portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty and turbinate reduction.

    Procedure: Septoplasty · Procedure: Inferior Turbinate Reduction

Interventions

  • ProcedureBatten batten graft

    The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.

  • ProcedureSeptoplasty

    A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.

  • ProcedureInferior Turbinate Reduction

    The bilateral inferior turbinates will be surgically ablated.

05

What researchers measure

Primary outcomes

  1. Nasal Obstruction Symptom Evaluation (NOSE) score

    1. The NOSE scale is a scoring scale from 0 to 4 (0 = no problem for quality of life, 4 = a severe problem) under 5 different parameters 2. The sum of 5 different parameters are added up to give a range of possible sums from 0-20. This sum is then multiplied by 5 to give a final score with range 0-100. Ref: Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and validation of the nasal obstruction symptom evaluation (NOSE) scale. Otolaryngol Head Neck Surg 2004;130:157-163

    Time frame: 12 months

Secondary outcomes

  1. Lateral Wall Insufficiency (LWI) scores

    Blinded, and derived by independent physician watching recorded videos 2. Grading system for lateral nasal wall collapse (0-100%). (1) Identify the junction of the upper and lower cartilages (black arrow) just above the recurvature of the lower lateral cartilage. (2) Imagine a line parallel to the nasal floor across to the septum. (3) Estimate the degree of collapse during inspiration as a percentage compared with repose. Ref: Tsao GJ, Fijalkowski N, Most SP. Validation of a grading system for lateral nasal wall insufficiency. Allergy Rhinol (Providence) 2013;4:e66-e68

    Time frame: 12 months

  2. Peak Inspiratory Flow Rate (PIFR)

    Peak inspiratory flow rate ( PIFR ) is the maximum amount of air that can be inhaled over the time course of 1 deep breath, measured in L/min. This will be measured with a nasal spirometer.

    Time frame: 12 months

  3. Complications and side-effects

    Measured using the the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Reference https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

    Time frame: 12 months

  4. Cost-effectiveness (EQ-5D-5L)

    EQ-5D-5L is a standardized measure of health-related quality of life and validated for QALYs in rhinology research. Estimated total cost of each treatment arm per patient/Estimated QALY derived from EQ-5D-5L per patient = cost-per-QALY Reference: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X Qual Life Res 2011 Dec;20(10):1727-1736

    Time frame: 12 month

  5. Reoperation incidence

    Measured as incidence of any reoperation within study follow-up period (12 months) divided by the number of total enrollees x 100%

    Time frame: 12 months

06

Study locations

2 of 3 sites recruiting
  • Poplar Bluff Regional Medical Center
    Poplar Bluff, Missouri 63901, United States
    Not yet recruiting
  • Lenox Hill Hospital/Staten Island University Hospital
    New York, New York 10075, United States
    • David Hiltzik, MD · Contact · Dhiltzik1@northwell.edu · 718-226-6110
    • David Hiltzik, MD · Principal investigator
    • Tristan Tham, MD · Sub investigator
    Recruiting
  • Staten Island University Hospital
    Staten Island, New York 10305, United States
    Recruiting
07

Registry details

Key details

Study ID
NCT05287841
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Apr 30, 2021
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Sep 20, 2024

Study contacts

Research Department
Contact
SIUHResearch@northwell.edu
718-226-6256
David Hiltzik, MD
Contact
dhiltzik1@northwell.edu
212-434-4500
David Hiltzik, MD
principal investigator · Northwell Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion